Merck Stock-Based Compensation 2010-2025 | MRK
Merck annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Merck stock-based compensation for the quarter ending March 31, 2025 was $195M, a 10.8% increase year-over-year.
- Merck stock-based compensation for the twelve months ending March 31, 2025 was $1.909B, a 18.35% increase year-over-year.
- Merck annual stock-based compensation for 2024 was $0.761B, a 17.98% increase from 2023.
- Merck annual stock-based compensation for 2023 was $0.645B, a 19.22% increase from 2022.
- Merck annual stock-based compensation for 2022 was $0.541B, a 12.94% increase from 2021.
Merck Annual Stock-Based Compensation
(Millions of US $) |
| 2024 |
$761 |
| 2023 |
$645 |
| 2022 |
$541 |
| 2021 |
$479 |
| 2020 |
$441 |
| 2019 |
$388 |
| 2018 |
$348 |
| 2017 |
$312 |
| 2016 |
$300 |
| 2015 |
$299 |
| 2014 |
$278 |
| 2013 |
$276 |
| 2012 |
$335 |
| 2011 |
$369 |
| 2010 |
$509 |
| 2009 |
$415 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$198.296B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
